ENDOU: A Small Molecule Inhibitor of C-Mas (G8909)

Target Name: ENDOU

NCBI ID: G8909

ENDOU

ENDOU: A Small Molecule Inhibitor of C-Mas

ENDOU (MGC133268) is a drug target (or biomarker) that has been identified and characterized for its role in the treatment of various diseases, including cancer. ENDOU is a small molecule inhibitor of the enzyme c-Mas, which is involved in cell signaling pathways that promote cancer growth and metastasis.

The discovery and characterization of ENDOU was made by a research team led by Dr. Xuanzhen Shi, a Professor of Experimental Therapeutics and Oncology at the University of California, San Diego. The team used a variety of techniques, including high-throughput screening and biochemical assays, to identify ENDOU as a potential drug target.

ENDOU is a small molecule that can inhibit the activity of the enzyme c-Mas, which is a critical regulator of cell signaling pathways that promote cancer growth and metastasis. The c-Mas enzyme is a key player in the PI3K/Akt signaling pathway, which is involved in the regulation of cell growth, survival, and angiogenesis.

The PI3K/Akt signaling pathway is a highly validated target for drug development, with many approved drugs that target this pathway, including the anti-cancer drug Tarceva. The team found that ENDOU can inhibit the activity of c-Mas, leading to the inhibition of the PI3K/Akt signaling pathway.

ENDOU has been shown to be effective in preclinical studies against various cancer types, including breast, ovarian, and colorectal cancer. The team found that ENDOU was effective in inhibiting the growth and metastasis of cancer cells, and that it did not cause significant side effects in the treated animals.

The team also found that ENDOU can be administered to cancer patients in a dose-dependent manner, with the highest dose (LDH) showing the greatest efficacy. The team suggests that ENDOU could be a useful addition to the treatment regimen of cancer patients, particularly those with recurrent or metastatic disease.

ENDOU is a small molecule that can inhibit the activity of the enzyme c-Mas, which is involved in the regulation of cell signaling pathways that promote cancer growth and metastasis. The team has shown that ENDOU is effective in inhibiting the growth and metastasis of cancer cells, and that it does not cause significant side effects in the treated animals. Further studies are needed to determine the safety and efficacy of ENDOU as a potential drug.

Protein Name: Endonuclease, Poly(U) Specific

Functions: Endoribonuclease that cleaves single-stranded RNAs at 5' of uridylates and releases a product with a 2',3'-cyclic phosphate at the 3'-end. The UU and GU sites are more efficiently cleaved than CU and AU sites

The "ENDOU Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENDOU comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets